Advertisement
SALT LAKE CITY--(BUSINESS WIRE)--BSD Medical Corporation, a leading provider of medical systems that utilize heat therapy to treat cancer, announced today that the Company is approaching 100 patients successfully treated with the MicroThermX® Microwave Ablation System (MicroThermX®) at hospitals throughout the U.S. These successful treatments have generated a revenue stream from sales of disposable SynchroWave antennas combined with highly profitable, fee-per-use equipment rental revenues. BSD has added the equipment rental program to maximize revenues from the MicroThermX® line of products. Clinicians have used the MicroThermX® to treat patients with cancers of the liver, lung, and kidneys.

"We have expanded our sales programs for the MicroThermX® to include the rental program in order to increase our market penetration," said Harold Wolcott, BSD President and CEO. "This program has demonstrated the potential to significantly increase future revenues, and we are very optimistic about its success. We are also encouraged by the positive feedback from the clinicians, the markets acceptance of the product, and the ongoing positive clinical results from patient treatments with the MicroThermX®."

About the MicroThermX® Microwave Ablation System

The MicroThermX® is a compact, mobile, state-of-the-art, proprietary system that includes a microwave generator, single-patient-use disposable antennas, and a thermistor-based temperature monitoring system. The innovative design of the MicroThermX® is the first of its kind that allows delivery of higher power levels using a single generator. The MicroThermX® utilizes innovative synchronous phased array technology that was developed and patented by BSD to provide larger and more uniform zones of ablation during a single procedure. The MicroThermX® introduces into the Companys product line innovative, high-end disposables (SynchroWave antennas) that are used in each ablation treatment and will provide a significant ongoing revenue stream. The soft tissue ablation world market potential is estimated to exceed $2.3 billion. The U.S. Food and Drug Administration (FDA) has granted the Company a 510(k) clearance to market the MicroThermX® for ablation of soft tissue. BSD has also received CE Marking for the MicroThermX® System, which allows BSD to market the MicroThermX® in Europe. CE Marking is also recognized in many countries outside of the EU, providing BSD the ability to market the MicroThermX® to a number of international markets.

About BSD Medical Corporation

BSD Medical Corporation develops, manufactures, markets and services systems to treat cancer and benign diseases using heat therapy, which is delivered using focused radiofrequency (RF) and microwave energy. BSDs product lines include both hyperthermia and ablation treatment systems. BSDs hyperthermia cancer treatment systems, which have been in use for several years in the United States, Europe and Asia, are used to treat certain tumors with heat (hyperthermia) while increasing the effectiveness of other therapies such as radiation therapy. BSDs microwave ablation system has been developed as a stand-alone therapy to employ precision-guided microwave energy to ablate (destroy) soft tissue. The Company has developed extensive intellectual property, multiple products in the market and established distribution in the United States, Europe and Asia. Certain of the Companys products have received regulatory approvals and clearances in the United States, Europe and China. For further information visit BSD Medical's website at www.BSDMedical.com.

Posted by Sean Fenske, Editor-in-Chief, MDT

Advertisement
Advertisement